Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s ...

Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe ...

This favorable landscape presents an opportunity for investors to explore fundamentally strong biotech stocks with promising ...

Following a downturn in M&A in 2024, the pharma and life sciences industry can expect to see a busier year in 2025.

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

The stock's fall snapped a two-day winning streak.

In 2024, startups saw a notable resurgence in large-scale funding rounds. By May, over 100 startups had secured funding ...